A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients with Advanced Breast Cancer

Study Status

Open to Enrollment

Study Description

The purpose of this study is to compare the incidence (a measure of the risk of developing a condition) and severity of neuropathy (numbness, tingling, pain or weakness in the hands and feet) for two treatment groups (eribulin versus ixabepilone) in patients with advanced breast cancer. 

Disease Status and/or Stage

Advanced Breast Cancer and Neuropathy



Key Eligibility

  • Women age 18 and older
  • Confirmed locally recurrent or metastatic breast cancer
  • Have received prior taxane therapy and at least one prior cytotoxic chemotherapy regimen for advanced breast cancer
  • Other eligibility criteria will be discussed with you when you contact the study team

Principal Investigator

Linda Vahdat, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Erica Bersin
Tel: (646) 962-8232
[email protected]

Top of page